



Review – Part of the Special Issue – Pharmacology in 21st Century Biomedical Research

Pharmacokinetics



Jianghong Fan, Inés A.M. de Lannoy*

InterVivo Solutions Inc., 120 Carlton Street, Suite 203, Toronto, ON, Canada M5A 4K2

ARTICLE INFO

Article history:

Received 16 May 2013

Accepted 9 September 2013

Available online 17 September 2013

Keywords:

Pharmacokinetics

Absorption

Distribution

Clearance

Metabolite kinetics

Pharmacodynamics

ABSTRACT

Pharmacokinetics (PK) is the study of the time course of the absorption, distribution, metabolism and excretion (ADME) of a drug, compound or new chemical entity (NCE) after its administration to the body. Following a brief introduction as to why knowledge of the PK properties of an NCE is critical to its selection as a lead candidate in a drug discovery program and/or its use as a functional research tool, the present article presents an overview of PK principles, including practical guidelines for conducting PK studies as well as the equations required for characterizing and understanding the PK of an NCE and its metabolite(s). A review of the determination of *in vivo* PK parameters by non-compartmental and compartmental methods is followed by a brief overview of allometric scaling. Compound absorption and permeability are discussed in the context of intestinal absorption and brain penetration. The volume of distribution and plasma protein and tissue binding are covered as is the clearance (systemic, hepatic, renal, biliary) of both small and large molecules. A section on metabolite kinetics describes how to estimate the PK parameters of a metabolite following administration of an NCE. Lastly, mathematical models used to describe pharmacodynamics (PD), the relationship between the NCE/compound concentration at the site of action and the resulting effect, are reviewed and linked to PK models in a section on PK/PD.

© 2013 Published by Elsevier Inc.

Contents

1. Introduction	94
2. Background	94
3. Overview of basic PK processes	95
3.1. Determination of <i>in vivo</i> PK parameters	96
3.1.1. Study design	96
3.1.2. Data analysis and interpretation	97
3.2.1. Non-compartmental analysis	97
3.2.2. Compartmental analysis	99
4. Pharmacokinetics scaling from animals to humans	100
4.1. Allometric scaling	100
4.2. Physiologically based PK (PBPK) modeling	101
5. Absorption and permeability	101
5.1. Intestinal absorption and permeability	101
5.1.1. Role of intestinal permeability and transporters	101
5.1.2. Solubility	101
5.1.3. Log <i>P</i> and log <i>D</i>	101
5.1.4. Caco-2 permeability assay	102
5.2. Brain permeability and penetration	102
6. Distribution and protein binding	103
6.1. Volume of distribution (<i>V</i> or <i>V_d</i>)	103
6.2. Plasma protein binding	104

* Corresponding author.

E-mail addresses: jianghongf@intervivo.com (J. Fan), inesd@intervivo.com, ines.delannoy@utoronto.ca (Inés A.M. de Lannoy).

6.3.	Tissue binding	104
7.	Clearance (metabolism and excretion)	104
7.1.	Systemic clearance (CL_s)	104
7.2.	Organ clearance	105
7.2.1.	Hepatic clearance	105
7.2.2.	Renal clearance	106
7.2.3.	Biliary clearance	107
7.3.	Clearance of large molecules	107
7.3.1.	Nano-sized particles and molecules	107
7.3.2.	Antibody drugs	108
7.3.3.	Peptides and proteins	108
8.	Metabolite kinetics	108
8.1.	Intravenous compound administration	108
8.1.1.	Formation rate-limited metabolite kinetics ($k \ll k_m$)	108
8.1.2.	Elimination rate-limited metabolite kinetics ($k \gg k_m$)	109
8.1.3.	Time to achieve the maximum metabolite concentration ($t_{max,m}$)	109
8.1.4.	Area under the plasma concentration versus time curve (AUC)	109
8.1.5.	Stead-state <i>i.v.</i> infusion	109
8.2.	Extravascular compound administration	109
8.2.1.	Area under the concentration versus time curve (AUC)	109
8.3.	Metabolite excretion in the urine	110
8.4.	Issues	110
8.4.1.	Absorption rate-limited kinetics	110
8.4.2.	Elimination rate-limited disposition	110
8.4.3.	First-pass metabolism	110
8.4.4.	Preformed and formed metabolite	111
8.4.5.	Pro-drug and metabolite	111
8.4.6.	Species differences	111
8.4.7.	Metabolite-parent compound interactions	111
9.	Pharmacokinetics and pharmacodynamics	111
9.1.	Pharmacological effects	111
9.1.1.	Quantal effect	112
9.1.2.	Graded effect	112
9.2.	Drug–target residence time	117
9.3.	Summary	117
10.	Conclusions	117
	References	118

1. Introduction

While potency, efficacy and selectivity are key attributes of a new chemical entity (NCE) that drive its characterization as a compound of potential interest in the drug discovery process or as a research tool that can be used to interrogate biological systems *in vitro* and *in vivo*, unless the pharmacokinetics (PK) properties of an NCE are known, its use *in vivo* becomes limited by shortcomings in PK that can confuse data interpretation and result in experimental outcomes that are invalid. For instance, when making species comparisons of plasma exposure of an NCE *in vivo*, without knowledge of the variations in plasma protein binding and metabolic liability across species, correlation of the pharmacological response with plasma exposure becomes challenging. As Hodgson has cogently noted [1] – “A chemical cannot be a drug, no matter how active nor how specific its action, unless it is also taken appropriately into the body (absorption), distributed to the right parts of the body, metabolized in a way that does not instantly remove its activity, and eliminated in a suitable manner – a compound must get in, move about, hang around, and then get out.” Thus, evaluating the properties of a compound, especially an NCE, *in vivo* without knowledge of its PK properties – even at a rudimentary level – is an exercise in futility. The present overview provides an introduction to the principles of PK, including guidelines for conducting PK studies and the equations required for characterizing and understanding the PK of an NCE and its possible metabolite(s).

2. Background

Pharmacokinetics (PK) is the study of the movement of xenobiotics (drugs/compounds/NCEs) within the body after their administration, whereas pharmacodynamics (PD) is the study of the relationship between the concentration of a compound/NCE at its site of action, where the therapeutic targets (e.g., receptors, transporters or enzymes) are located, and the magnitude of the pharmacological response. In the simplest of terms, what distinguishes PK from PD is that the former describes what the body does to the compound, whereas PD describes what the compound does to the body [2]. Both fields of study are important for investigating the disposition profiles and pharmacological efficacy of compounds/NCEs in the body [3], and may be influenced by experimental as well as clinical conditions (e.g., gender, species, age, disease state).

In the past, drug discovery programs often concentrated their efforts solely on selecting the most potent or efficacious compound in *in vitro* receptor binding or functional assays, respectively, that were designed to test hundreds to thousands of compounds, and failed to generate data on whether a compound would have the ability to reach its therapeutic target at a sufficient concentration and for a sufficient amount of time to alter target function when administered *in vivo*. This strategy was noted as being detrimental to developing a successful drug, with a retrospective analysis of 7 U.K. owned pharmaceutical companies conducted up to 1985 revealing that 39% of NCEs failed in the clinic due to poor PK properties [4]. Careful assessment of the PK profile in selecting and

Download English Version:

<https://daneshyari.com/en/article/2512415>

Download Persian Version:

<https://daneshyari.com/article/2512415>

[Daneshyari.com](https://daneshyari.com)